RS67656B1 - Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora - Google Patents

Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora

Info

Publication number
RS67656B1
RS67656B1 RS20251325A RSP20251325A RS67656B1 RS 67656 B1 RS67656 B1 RS 67656B1 RS 20251325 A RS20251325 A RS 20251325A RS P20251325 A RSP20251325 A RS P20251325A RS 67656 B1 RS67656 B1 RS 67656B1
Authority
RS
Serbia
Prior art keywords
formulation
fusion protein
vegf receptor
microliters
receptor fusion
Prior art date
Application number
RS20251325A
Other languages
English (en)
Serbian (sr)
Inventor
Kenneth S Graham
Saurabh Wadhwa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66669104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS67656(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of RS67656B1 publication Critical patent/RS67656B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RS20251325A 2018-05-10 2019-05-10 Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora RS67656B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862669506P 2018-05-10 2018-05-10
US201862752127P 2018-10-29 2018-10-29
US201862769876P 2018-11-20 2018-11-20
US201962813882P 2019-03-05 2019-03-05
EP24156902.9A EP4364724B1 (en) 2018-05-10 2019-05-10 High concentration vegf receptor fusion protein containing formulations

Publications (1)

Publication Number Publication Date
RS67656B1 true RS67656B1 (sr) 2026-02-27

Family

ID=66669104

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20251325A RS67656B1 (sr) 2018-05-10 2019-05-10 Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora

Country Status (28)

Country Link
US (4) US11103552B2 (https=)
EP (3) EP3790532A1 (https=)
JP (3) JP7235770B2 (https=)
KR (1) KR20210021299A (https=)
CN (5) CN121570417A (https=)
AU (3) AU2019265005B2 (https=)
BR (1) BR112020022610A2 (https=)
CA (2) CA3099551C (https=)
CL (3) CL2020002872A1 (https=)
CO (1) CO2020014427A2 (https=)
DK (1) DK4364724T3 (https=)
ES (1) ES3056525T3 (https=)
FI (1) FI4364724T3 (https=)
HR (1) HRP20260001T1 (https=)
IL (2) IL318714A (https=)
JO (1) JOP20200275A1 (https=)
LT (1) LT4364724T (https=)
MA (1) MA52570A (https=)
MX (3) MX421310B (https=)
MY (1) MY204232A (https=)
NZ (1) NZ770284A (https=)
PH (1) PH12020551839A1 (https=)
PL (1) PL4364724T3 (https=)
PT (1) PT4364724T (https=)
RS (1) RS67656B1 (https=)
SG (1) SG11202010684YA (https=)
SI (1) SI4364724T1 (https=)
WO (1) WO2019217927A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
JP6187777B2 (ja) 2011-06-13 2017-08-30 シーエスエル、リミテッド Ｇ−ｃｓｆｒに対する抗体およびその使用
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP4621067A3 (en) 2017-05-05 2025-11-19 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
JP7536640B2 (ja) 2017-11-17 2024-08-20 アムジエン・インコーポレーテツド ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤
CA3081770A1 (en) 2017-11-29 2019-06-06 Csl Limited Method of treating or preventing ischemia-reperfusion injury
EP4122486A1 (en) 2017-11-30 2023-01-25 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat diabetic retinopathy
KR102742284B1 (ko) * 2017-12-22 2024-12-16 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
EP3873519A1 (en) 2018-10-29 2021-09-08 F. Hoffmann-La Roche AG Antibody formulation
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
US11180540B2 (en) 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
CN115698245A (zh) * 2020-01-27 2023-02-03 百时美施贵宝公司 等电聚焦样品基质
EP4142792A4 (en) 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
EP4172351A4 (en) * 2020-06-26 2024-08-14 Trefoil Therapeutics, Inc. RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THERAPEUTIC USES THEREOF
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
CA3189030A1 (en) * 2020-07-07 2022-01-13 Kanaph Therapeutics Inc. Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof
BR112023003548A2 (pt) * 2020-09-03 2023-04-04 Univ Massachusetts Vírus adenoassociado para liberação de kh902 (conbercept) e usos do mesmo
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4259103A1 (en) * 2020-12-10 2023-10-18 Stemline Therapeutics Inc. Improved lyophilized formulation
KR20230122034A (ko) * 2020-12-16 2023-08-22 씨에스엘 이노베이션 피티와이 엘티디 단백질 제형물 및 이의 용도
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
MX2023009614A (es) * 2021-02-17 2023-08-24 Arecor Ltd Composicion acuosa de una construccion de proteina modificada geneticamente que comprende un dominio fc.
US20240156907A1 (en) * 2021-03-16 2024-05-16 Kashiv Biosciences, Llc Novel formulation of fusion protein
CN117083305A (zh) * 2021-03-25 2023-11-17 南京金斯瑞生物科技有限公司 抗体融合蛋白及其用途
IL308505A (en) 2021-05-17 2024-01-01 Regeneron Pharma Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
CN113289029B (zh) * 2021-05-20 2023-09-05 上海赛金生物医药有限公司 一种单克隆抗体-细胞因子融合蛋白制剂
EP4398877A1 (en) * 2021-09-06 2024-07-17 LEK Pharmaceuticals d.d. Formulations for vegf receptor fusion proteins
AU2023233561A1 (en) 2022-03-15 2024-09-19 Bayer Healthcare Llc Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CN119365206A (zh) 2022-03-15 2025-01-24 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
WO2023206134A1 (en) * 2022-04-27 2023-11-02 Beijing Sightnovo Medical Technology Co., Ltd Compositions and methods for eye diseases
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
IL319100A (en) * 2022-09-01 2025-04-01 Vegenics Pty Ltd Pharmaceutical preparation and method for using it
CN119584953A (zh) * 2022-09-16 2025-03-07 齐鲁制药有限公司 一种稳定的高浓度自缓冲药物组合物
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
KR20250143315A (ko) * 2023-02-10 2025-10-01 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항-vegfa 및 vegfc 이중특이적 결합 단백질을 포함하는 약제학적 제제
WO2024263995A1 (en) 2023-06-23 2024-12-26 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
WO2025122670A1 (en) * 2023-12-05 2025-06-12 Kodiak Sciences Inc. Formulations for dual vegf/il-6 inhibitors, anti-vegf antibodies, and conjugates thereof
WO2025177156A1 (en) * 2024-02-20 2025-08-28 Lupin Limited Stable ophthalmic pharmaceutical formulation of aflibercept
WO2025217334A1 (en) * 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations
WO2025217676A1 (en) * 2024-04-15 2025-10-23 CSL Innovation Pty Ltd Protein formulations and uses thereof
WO2025219484A1 (en) 2024-04-16 2025-10-23 Alvotech Hf High concentration aflibercept formulations
CN118108862B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗血管新生的融合蛋白及其应用

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN100523187C (zh) 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2002335046A1 (en) 2001-10-19 2003-05-06 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
WO2003035028A1 (en) 2001-10-19 2003-05-01 Nektar Therapeutics Modulating charge density to produce improvements in the characteristics of spray-dried proteins
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050196340A1 (en) 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
CA2534197A1 (en) 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
KR100897379B1 (ko) 2004-06-08 2009-05-14 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관신생-저해 키메릭 단백질 및 그 사용
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PL1802334T3 (pl) 2004-10-21 2013-01-31 Genentech Inc Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
ES2390354T3 (es) 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
JP2009504571A (ja) 2005-07-25 2009-02-05 トルービオン ファーマスーティカルズ インコーポレイテッド タンパク質解離のための組成物および方法
CN101312744A (zh) 2005-11-22 2008-11-26 惠氏公司 免疫球蛋白融合蛋白制剂
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
US7608261B2 (en) 2006-06-16 2009-10-27 Regeneron Pharmacuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
ES2968301T3 (es) 2008-08-05 2024-05-08 Wyeth Llc Liofilización por encima del colapso
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010263058A1 (en) 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2010148321A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Slow dissolution method for reconstitution of lyophilized material
CA2765220A1 (en) 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
RU2012108108A (ru) 2009-08-04 2013-09-10 Дженентек, Инк. Концентрированные полипептидные лекарственные формы с пониженной вязкостью
US20130029909A1 (en) 2009-09-15 2013-01-31 John Ryan Treatment of cancer
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US9956165B2 (en) 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
KR20130060227A (ko) 2010-05-03 2013-06-07 제넨테크, 인크. 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
EP2588138A1 (en) 2010-07-02 2013-05-08 Genentech, Inc. Treatment of vascularized pigment epithelial detachment with anti-vegf therapy
US20130274692A1 (en) 2010-08-05 2013-10-17 Yair Alster Subconjuctival implant for posterior segment drug delivery
CN103816115B (zh) * 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
KR20260004598A (ko) 2011-01-13 2026-01-08 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
KR102081808B1 (ko) 2011-04-25 2020-02-26 아이콘 바이오사이언스, 인크. 주사기용 투여량 가이드
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
GB201122408D0 (en) 2011-12-23 2012-02-08 Univ Strathclyde Method for preparing dry protein formulations
AU2013212587B2 (en) 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
LT3679922T (lt) 2012-06-01 2021-10-25 Novartis Ag Švirkštas
AU2013267310A1 (en) 2012-06-01 2014-12-11 Ophthotech Corporation Compositions comprising an anti-PDGF aptamer and a VEGF antagonist
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
DE202013000688U1 (de) 2012-07-03 2013-03-05 Novartis Ag Glas-Spritze
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2916827B1 (en) 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
JP6026002B2 (ja) 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
EP3744728A1 (en) 2013-02-12 2020-12-02 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
EP3003369A4 (en) 2013-05-28 2017-04-26 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions comprising pyrophosphate
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
CA2927012A1 (en) 2013-11-05 2015-05-14 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
RU2702748C2 (ru) 2014-05-12 2019-10-11 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
CA2952609A1 (en) 2014-06-26 2015-12-30 Amgen Inc. Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN104940926B (zh) 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
PT3230316T (pt) 2014-12-11 2022-02-24 Bayer Healthcare Llc Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
CN108348572B (zh) * 2015-03-31 2021-06-29 日东制药株式会社 含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
PH12017501857B1 (en) 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
AU2016297178A1 (en) 2015-07-22 2018-01-25 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
US20230134160A1 (en) 2015-09-22 2023-05-04 Pfizer Inc. Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method
RU2763916C2 (ru) 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
WO2017066554A1 (en) 2015-10-16 2017-04-20 Regeneron Pharmaceuticals, Inc. Stable protein compositions
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
CN108290004A (zh) 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
WO2017087798A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
JP2018535242A (ja) 2015-11-30 2018-11-29 メディミューン，エルエルシー 高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比
PT3384049T (pt) 2015-12-03 2023-08-18 Regeneron Pharma Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
JP6942135B2 (ja) 2016-01-25 2021-09-29 サノフイＳａｎｏｆｉ 血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
US20190060241A1 (en) 2016-04-13 2019-02-28 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
DK3471780T3 (da) 2016-06-16 2020-11-23 Adverum Biotechnologies Inc Behandling af amd med aav2-variant med aflibercept
WO2018013673A1 (en) 2016-07-13 2018-01-18 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
SG11201901081XA (en) 2016-08-17 2019-03-28 Boehringer Ingelheim Int Process for the preparation of highly concentrated liquid formulations containing biomolecules
DK3500856T3 (da) 2016-08-18 2020-12-14 Regeneron Pharma Assay til bestemmelse af et proteins potentiale for at selvassociere ved hjælp af koncentrationsafhængig selvinteraktionsnanopartikelspektroskopi
AU2017317129B2 (en) 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
CA3038894A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
CA3039655A1 (en) 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
EP3549608A4 (en) 2016-12-01 2020-08-12 Jiangsu Hengrui Medicine Co., Ltd. USE OF A COMBINATION OF A VEGFR INHIBITOR AND PARP INHIBITOR IN THE MANUFACTURING OF A MEDICINAL PRODUCT FOR TREATMENT OF STOMACH CANCER
US11123411B2 (en) 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
US20200368331A1 (en) 2016-12-08 2020-11-26 Gary E. Borodic Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals
CR20190291A (es) 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
AU2018258654B2 (en) 2017-04-27 2022-01-06 The Johns Hopkins University Dendrimer compositions for use in angiography
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
US20200108064A1 (en) 2017-06-08 2020-04-09 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
AU2018306303A1 (en) 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
WO2019036619A1 (en) 2017-08-18 2019-02-21 Reform Biologics, Llc STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN
IT201700101582A1 (it) 2017-09-12 2019-03-12 Milano Politecnico Dispositivo per rilascio intraoculare
IL272513B2 (en) 2017-09-15 2023-04-01 Amgen Inc Lyophilization process for pharmaceutical formulation of medical protein
MA50174A (fr) 2017-09-18 2020-07-29 Amgen Inc Formules de protéines de fusion vegfr-fc
WO2019066603A1 (ko) 2017-09-29 2019-04-04 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
US11246846B2 (en) 2017-10-23 2022-02-15 Michael S. Tempesta Trisodium citrate compositions having enhanced uptake across digestive mucosa
WO2019099786A1 (en) 2017-11-16 2019-05-23 Ophthotech Corporation A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv)
JP7536640B2 (ja) 2017-11-17 2024-08-20 アムジエン・インコーポレーテツド ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤
CA3081094A1 (en) 2017-11-20 2019-05-23 Alison J. GILLESPIE Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP4122486A1 (en) 2017-11-30 2023-01-25 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat diabetic retinopathy
CA3080644A1 (en) 2017-12-06 2019-06-13 Quanren WANG Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
KR102742284B1 (ko) * 2017-12-22 2024-12-16 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
FI3743091T3 (fi) 2018-01-26 2025-01-03 Univ California Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
EP3761953A1 (en) 2018-03-08 2021-01-13 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
KR102791798B1 (ko) 2018-04-12 2025-04-07 암젠 인크 안정한 단백질 조성물의 제조 방법
WO2019212211A1 (en) 2018-04-30 2019-11-07 Gachon University Of Industry-Academic Cooperation Foundation Antiangiogenic chromane derivative and uses thereof
CN108671229B (zh) 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
WO2020055123A1 (ko) 2018-09-10 2020-03-19 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
WO2020087003A1 (en) 2018-10-26 2020-04-30 Amgen Inc. Formulations comprising a tris buffer and a protein
CN110664757B (zh) 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
WO2020106948A1 (en) 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
CA3122227A1 (fr) 2018-12-20 2020-06-25 Laboratoires Thea Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
CA3127228A1 (en) 2019-01-30 2020-08-06 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
JP7663501B2 (ja) 2019-02-11 2025-04-16 スロゼン オペレーティング， インコーポレイテッド 眼障害におけるｗｎｔシグナル伝達の調節
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
WO2020255135A1 (en) 2019-06-17 2020-12-24 Sol-Gel Technologies Ltd. Treatment of ocular inflammatory diseases with topical ophthalmic tapinarof compositions
US20200390725A1 (en) 2019-06-17 2020-12-17 Sol-Gel Technologies Ltd. Treatment of ocular diseases with ophthalmic tapinarof compositions
US20200390724A1 (en) 2019-06-17 2020-12-17 Sol-Gel Technologies Ltd. Treatment of ocular diseases with ophthalmic tapinarof compositions
MY204342A (en) 2019-03-25 2024-08-24 Alteogen Inc Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
BR112021019612A2 (pt) 2019-04-01 2021-11-30 Genentech Inc Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
US20220184186A1 (en) 2019-04-03 2022-06-16 Denali Therapeutics Inc. Formulations of protein molecules comprising iduronate 2-sulfatase
US12599669B2 (en) 2019-04-23 2026-04-14 Amgen Inc. Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
EP3736574A1 (en) 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
TW202110454A (zh) 2019-05-30 2021-03-16 大陸商江蘇恒瑞醫藥股份有限公司 Cdk4/6抑制劑與vegfr抑制劑聯合在製備治療腫瘤的藥物中的用途
KR20220034169A (ko) 2019-07-10 2022-03-17 리제너론 파아마슈티컬스, 인크. 감소된 수준의 숙주 세포 단백질을 포함하는 방법 및 조성물
CA3145239A1 (en) 2019-08-06 2021-02-11 Hugh LIN Personalized treatment of ophthalmologic diseases
US20210100856A1 (en) 2019-09-11 2021-04-08 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
AU2020345174A1 (en) 2019-09-12 2022-03-31 Lupin Limited Modified dosing of VEGF inhibitors for ophthalmic use
US20220340630A1 (en) 2019-09-13 2022-10-27 National Science And Technology Development Agency Composition of renaturation buffer solution for dimeric proteins and method of renaturation dimeric proteins using the composition thereof
CA3154653A1 (en) 2019-09-17 2021-03-25 Merck Patent Gmbh Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
AU2020384917A1 (en) 2019-11-15 2022-03-31 F. Hoffmann-La Roche Ag Prevention of visible particle formation in aqueous protein solutions
US20230355544A1 (en) 2019-12-03 2023-11-09 Sichuan Honghe Biotechnology Co., Ltd Pharmaceutical Composition Containing Elemene, Preparation Method Therefor, And Use Thereof
AU2020397053A1 (en) 2019-12-06 2022-06-23 Regeneron Pharmaceuticals, Inc. VEGF mini-traps and methods of use thereof
US11180540B2 (en) 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
WO2021125852A1 (ko) 2019-12-17 2021-06-24 주식회사 프로젠 신규 주사제 제형
CN115279406A (zh) 2020-01-13 2022-11-01 阿帕特夫研究和发展有限公司 蛋白质治疗剂的调配物
WO2021168218A1 (en) 2020-02-19 2021-08-26 Clearside Biomedical, Inc. Compositions comprising axitinib and methods of treating ocular disorders
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
CN115279405B (zh) 2020-04-10 2025-02-18 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途
US20230272041A1 (en) 2020-04-22 2023-08-31 Dragonfly Therapeutics, Inc. Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins
AU2021287906B2 (en) 2020-06-11 2025-09-11 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
US11944663B2 (en) 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
EP4178530A1 (en) 2020-07-09 2023-05-17 F. Hoffmann-La Roche AG Concentrated compositions of proteins, their preparation and use thereof
WO2022011323A1 (en) 2020-07-10 2022-01-13 Iconic Therapeutics, Inc. Ocular disease treatment using anti-tissue factor antibodies
MX2023000557A (es) 2020-07-13 2023-02-13 Merck Patent Gmbh Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas.
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
EP4188384A1 (en) 2020-07-29 2023-06-07 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
US20230312683A1 (en) 2020-07-31 2023-10-05 Celltrion Inc. Stable pharmaceutical preparation
DE102020005002A1 (de) 2020-08-17 2022-02-17 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Mittel zur Therapie von Tumorerkrankungen
WO2022056326A1 (en) 2020-09-11 2022-03-17 Elixir Medical Corporation Anticoagulant compounds, methods and devices for ophthalmic use
EP4236986A1 (en) 2020-10-30 2023-09-06 Gemini Therapeutics Sub, Inc. Methods for treating inflammatory ocular diseases with complement factor h
MX2023004839A (es) 2020-10-30 2023-06-29 Eluminex Biosciences Suzhou Ltd Inhibidores de factores angiogenicos.
JP2023549776A (ja) 2020-11-13 2023-11-29 アストラゼネカ・ユーケイ・リミテッド 医薬製剤
CA3197627A1 (en) 2020-11-18 2022-05-27 Kimberly SHEPARD Inhalable dry powder formulations comprising angiogenesis inhibitors
FI20215186A1 (en) 2021-02-19 2022-08-20 Rebio Tech Oy Compositions for ophthalmic treatment
US20240156907A1 (en) 2021-03-16 2024-05-16 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022201084A1 (en) 2021-03-26 2022-09-29 Novartis Ag Methods for treating ocular diseases
CA3210368A1 (en) 2021-04-09 2022-10-13 Shengjiang Liu Compositions and methods for ocular transgene expression
JP2024515459A (ja) 2021-04-27 2024-04-10 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用する眼疾患の治療方法
WO2022229932A1 (en) 2021-04-29 2022-11-03 Einar Stefansson Hypoxia inducible factor (hif) inhibitors for treatment of atrophy associated with retinal hypoxia
IL308505A (en) 2021-05-17 2024-01-01 Regeneron Pharma Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
WO2023001288A1 (zh) 2021-07-23 2023-01-26 百奥泰生物制药股份有限公司 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用
US20240358855A1 (en) 2021-08-18 2024-10-31 University Of Utah Research Foundation Multigene constructs for treatment of age-related macular degeneration and other complement dysregulation-related conditions
EP4398877A1 (en) 2021-09-06 2024-07-17 LEK Pharmaceuticals d.d. Formulations for vegf receptor fusion proteins
EP4147709A1 (en) 2021-09-14 2023-03-15 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth A composition comprising il-36 and/or il-18 for use in treating ocular disorders
EP4424301A4 (en) 2021-10-29 2025-11-19 Alteogen Inc Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product

Also Published As

Publication number Publication date
MA52570A (fr) 2021-03-17
BR112020022610A2 (pt) 2021-02-09
KR20210021299A (ko) 2021-02-25
AU2024100037B4 (en) 2025-04-10
PH12020551839A1 (en) 2021-06-28
LT4364724T (lt) 2026-01-12
CL2023003448A1 (es) 2024-07-19
JP7235770B2 (ja) 2023-03-08
FI4364724T3 (fi) 2026-01-05
CA3099551C (en) 2025-08-19
EP4684776A2 (en) 2026-01-28
CN112739323A (zh) 2021-04-30
PT4364724T (pt) 2025-12-16
US20250121030A1 (en) 2025-04-17
EP4684776A3 (en) 2026-04-22
US12168036B2 (en) 2024-12-17
IL278375B1 (en) 2025-03-01
NZ770284A (en) 2025-11-28
CA3099551A1 (en) 2019-11-14
SI4364724T1 (sl) 2026-01-30
JOP20200275A1 (ar) 2020-11-02
CO2020014427A2 (es) 2020-12-21
MY204232A (en) 2024-08-16
CN116585466A (zh) 2023-08-15
AU2019265005A1 (en) 2020-12-17
MX2025001448A (es) 2025-03-07
EP4364724B1 (en) 2025-11-26
MX2020011848A (es) 2021-03-29
PL4364724T3 (pl) 2026-02-23
CL2021001957A1 (es) 2022-04-08
US20190343918A1 (en) 2019-11-14
CN121421956A (zh) 2026-01-30
HRP20260001T1 (hr) 2026-02-27
US20210353714A1 (en) 2021-11-18
SG11202010684YA (en) 2020-11-27
US11103552B2 (en) 2021-08-31
CN118948760A (zh) 2024-11-15
AU2024100037A4 (en) 2024-10-24
AU2019265005B2 (en) 2025-03-13
MX2024014765A (es) 2025-01-09
DK4364724T3 (da) 2025-12-22
CL2020002872A1 (es) 2021-03-26
WO2019217927A1 (en) 2019-11-14
ES3056525T3 (en) 2026-02-23
EP4364724A2 (en) 2024-05-08
AU2025204229A1 (en) 2025-06-26
MX421310B (es) 2025-03-14
JP7791125B2 (ja) 2025-12-23
CN121570417A (zh) 2026-02-27
EP4364724A3 (en) 2024-08-07
IL278375A (https=) 2020-12-31
JP2026058347A (ja) 2026-04-03
CA3281979A1 (en) 2026-03-02
EP3790532A1 (en) 2021-03-17
IL278375B2 (en) 2025-07-01
JP2021523162A (ja) 2021-09-02
IL318714A (en) 2025-03-01
CN112739323B (zh) 2025-11-25
JP2023071798A (ja) 2023-05-23
US20240058418A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
US12168036B2 (en) Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins
US11071780B2 (en) Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
AU2025226774A1 (en) Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
CA3097061A1 (en) Viscosity reduction of highly concentrated protein formulations
US20230270670A1 (en) Ophthalmic liquid composition
HK40106296B (en) High concentration vegf receptor fusion protein containing formulations
HK40106296A (en) High concentration vegf receptor fusion protein containing formulations
EA046718B1 (ru) Составы, содержащие слитый белок рецептора фрэс в высокой концентрации
HK40052983A (zh) 含有高浓度vegf受体融合蛋白的制剂
HK40052983B (zh) 含有高浓度vegf受体融合蛋白的制剂
WO2024254395A2 (en) Clec9a-based chimeric protein formulations
WO2023281367A1 (en) Stable liquid formulations of aflibercept